u/maintenance_mode_max

With a week-long half-life, exposure declines over several weeks after the last dose rather than stopping with it. The lag is why the first fortnight is uninformative.

Disagree. That is a preclinical finding in a rodent model and you are stating it as human pharmacology.

With a week-long half-life, exposure declines over several weeks after the last dose rather than stopping with it. The lag is why the first fortnight is uninformative.

receptor distribution is why the side effects are where they are

Left up. It is honest about the reason for stopping and about the timeline.

What are you planning to watch for, and over what period?

Left up. It is a maintenance report with a duration attached and those are rarer than they should be.

Left up. It is honest about the reason for stopping and about the timeline.

Agreed — the incretin effect is the load-bearing concept and everything downstream reads differently once you have it.

What is prompting the decision — cost, supply, side effects, or something else?

Adding the one process step — write down where you are before you change anything.

Edited a comment framing regain as a moral failure. The documented outcome is not a character verdict.

Left up. It is honest about the reason for stopping and about the timeline.

retrospective logs drift, contemporaneous ones do not

Receptor expression in a tissue is necessary but not sufficient for an effect. You also need the agonist to reach it at relevant exposure, and that is where a lot of confident mechanism talk falls down.

lean mass loss during weight loss is expected, the question is how much

Push back: a receptor being expressed in a tissue does not tell you the agonist reaches it at therapeutic exposure.

The half-life explanation was the thing that made weekly dosing intuitive for me rather than arbitrary.

Does the effect persist with continued dosing or does tolerance develop?

do not chase the last two kilos with a dose increase